Quingestanol acetate (Compound)

Synonyms:QUINGESTANOL ACETATE, 3000-39-3, UNII-M33GGZ63KG, Quingestanol acetate [USAN], W 4540, Norethindrone acetate 3-cyclopentyl enol ether, M33GGZ63KG, Quingestanol acetate (USAN), [(8R,9S,10R,13S,14S,17R)-3-cyclopentyloxy-17-ethynyl-13-methyl-2,7,8,9,10,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate, EINECS 221-078-4, BRN 2186975, 3-Cyclopentyl enol ether of norethindrone acetate, 3-(Cyclopentyloxy)-19-nor-17-alpha-pregna-3,5-dien-20-yn-17-ol acetate, 3-(Cyclopentyloxy)-19-nor-17alpha-pregna-3,5-dien-20-yn-17-ol acetate, 3-(Cyclopentyloxy)-19-nor-17alpha-pregna-3,5-dien-20-yn-17-yl acetate, 19-Nor-17-alpha-pregna-3,5-dien-20-yn-17-ol, 3-(cyclopentyloxy)-, acetate (ester), 3-(Cyclopentyloxy)-19-nor-17-alpha-pregna-3,5-dien-20-yn-17-ol acetate (ester), SCHEMBL282347, CHEMBL2105291, DTXSID50952409, CHEBI:135661, 19-Nor-17-alpha-pregna-3,5-dien-20-yn-17-ol, 3-(cyclopentyloxy)-, acetate, DB14679, 19-Norpregna-3,5-dien-20-yn-17-ol, 3-(cyclopentyloxy)-, acetate, (17alpha)-, D05679, Q7272228, 3-(Cyclopentyloxy)-19-norpregna-3,5-dien-20-yn-17-yl acetate, [(8R,9S,10R,13S,14S,17R)-3-Cyclopentyloxy-17-ethynyl-13-methyl-2,7,8,9,10,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]acetate
Pubchem:PUBCHEM:18142
Id:f5179f75-befe-5fb5-b708-b1d2e68f4f11
Description:nan

Analyze

Data Distillery
CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View Quingestanol acetate's neighborhood in the knowledge graph.

Gene and Drug Landing Page Aggegrator
GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for Quingestanol acetate.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with Quingestanol acetate.

This repository is under review for potential modification in compliance with Administration directives.